Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents
Public ClinicalTrials.gov record NCT03567291. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an otherwise open-label, single-arm study that includes a 2-week, double-blind, placebo controlled, randomized drug withdrawal period followed by a 3 week blinded maintenance or re-titration, and then a maintenance period. This study aims to evaluate the safety and efficacy of TEV-50717 tablets in patients with tics associated with TS who have previously completed participation in any of the parent studies.
Study identification
- NCT ID
- NCT03567291
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 228 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 6 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 24, 2018
- Primary completion
- May 14, 2020
- Completion
- May 14, 2020
- Last update posted
- Nov 8, 2021
2018 – 2020
United States locations
- U.S. sites
- 33
- U.S. states
- 18
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 046-0104 | Dothan | Alabama | 36303 | — |
| Teva Investigational Site 046-0107 | Rogers | Arkansas | 72758 | — |
| Teva Investigational Site 046-0126 | Anaheim | California | 92805 | — |
| Teva Investigational Site 046-0101 | Sacramento | California | 95815 | — |
| Teva Investigational Site 046-0111 | San Diego | California | 92108 | — |
| Teva Investigational Site 060-0160 | Gainesville | Florida | 32608 | — |
| Teva Investigational Site 060-0166 | Gulf Breeze | Florida | 32561-4458 | — |
| Teva Investigational Site 060-0161 | Miami | Florida | 33136-2107 | — |
| Teva Investigational Site 046-0115 | Orlando | Florida | 32803 | — |
| Teva Investigational Site 060-0153 | Orlando | Florida | 32819 | — |
| Teva Investigational Site 046-0114 | St. Petersburg | Florida | 33701 | — |
| Teva Investigational Site 046-0116 | Atlanta | Georgia | 30331 | — |
| Teva Investigational Site 060-0155 | Chicago | Illinois | 60612 | — |
| Teva Investigational Site 060-0164 | Chicago | Illinois | 60634 | — |
| Teva Investigational Site 046-0133 | Naperville | Illinois | 60563 | — |
| Teva Investigational Site 046-0128 | Boston | Massachusetts | 02114 | — |
| Teva Investigational Site 060-0170 | Bridgeton | Missouri | 63044 | — |
| Teva Investigational Site 046-0110 | Saint Charles | Missouri | 63304 | — |
| Teva Investigational Site 046-0134 | Lincoln | Nebraska | 68526-9467 | — |
| Teva Investigational Site 046-0109 | Voorhees Township | New Jersey | 08043 | — |
| Teva Investigational Site 046-0124 | New York | New York | 10029 | — |
| Teva Investigational Site 060-0154 | New York | New York | 10036 | — |
| Teva Investigational Site 046-0102 | Rochester | New York | 14618 | — |
| Teva Investigational Site 046-0106 | Oklahoma City | Oklahoma | 73116 | — |
| Teva Investigational Site 060-0169 | Charleston | South Carolina | 29414-5834 | — |
| Teva Investigational Site 060-0156 | Nashville | Tennessee | 37232-2551 | — |
| Teva Investigational Site 046-0113 | Dallas | Texas | 75243 | — |
| Teva Investigational Site 060-0163 | Fort Worth | Texas | 76104 | — |
| Teva Investigational Site 046-0108 | Houston | Texas | 77030 | — |
| Teva Investigational Site 046-0120 | San Antonio | Texas | 78249 | — |
| Teva Investigational Site 046-0105 | Orem | Utah | 84058 | — |
| Teva Investigational Site 046-0118 | Petersburg | Virginia | 23805 | — |
| Teva Investigational Site 060-0162 | Everett | Washington | 98201-4077 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03567291, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 8, 2021 · Synced Sep 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03567291 live on ClinicalTrials.gov.